Combivir Market Seen Soaring 3% Growth to Reach USD Million by 2030, Projects Univdatos Market Insights
- Vikas Kumar
- November 14, 2023
- HEALTHCARE, NEWS
- Combivir, Combivir Market, Combivir Market analysis, Combivir Market forecast, Combivir Market growth, Combivir Market share, Combivir Market trends
- 0 Comments
Key Highlights of the Report:
- Growing demand in the healthcare sector: The combivir market is experiencing significant growth due to increasing demand in the healthcare sector, driven by growing concerns over widespread drug addiction cases.
- Rise in pharmaceutical market: There has been growing demand for pharmaceuticals owing to increased incidences of HIV/AIDS.
- FDA-approval Timeline: The FDA-approval timeline of branded and generic Combivir drugs.
According to a new report by Univdatos Market Insights, Combivir Market is expected to reach USD Million in 2030 by growing at a CAGR of 3%. Combivir is the brand name for a combination of drugs lamivudine and zidovudine used to treat Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. These drugs act as antiretroviral agents and fight against HIV by competitively inhibiting and reducing the activity of reverse transcriptase. Combivir is generally used to fight against human immunodeficiency virus. While considering types, the generic drug type held the maximum share compared to the branded drug type owing to its cost-effectiveness. Several factors are contributing to the growth of combivir including the increased cases of drug addiction, the surge in awareness programs regarding HIV/AIDS, and rising investments in healthcare departments are driving the growth of combivir. Apart from these factors, rising strategic collaborations for HIV therapeutics are leading the market of combivir in this forecast period. For instance, in June 2023, U.S.-based A-Alpha Bio collaborated with Gilead to enhance HIV therapeutic options.
Access Sample PDF Here- https://univdatos.com/get-a-free-sample-form-php/?product_id=49099
The report suggests that the Rising Number of Launches and Approvals of Generics is one of the major factors driving the growth of the combivir market during the forthcoming years. Combivir generic development has gained support in terms of research and development in pharmaceutical industries. Money is an essential factor for gaining prominence in the market and HIV therapeutics research is attracting a huge load of money investments. This expenditure is driving the market for the development of new generics of combivir, which are much more effective and cost-saving. In recent years, there has been an increasing number of launches, FDA approvals, and an increasing number of technological advancements focused on HIV/AIDS along with multiple government initiatives for controlling HIV transmission. For instance, the U.S.-based Department of Health and Human Services (HHS) initiated a program the ‘ Ending the HIV Epidemic (EHE)’ in 2019 with an ambitious goal of reducing all new HIV infections in the U.S. by 90% by 2030. HHS has also provided multiple funding opportunities to jurisdictions, including simultaneous investments in sexually transmitted diseases specialty clinics. It also provides hope for patients to get better care and support through combivir, also it can serve as a doorway of opportunities for offering better treatment options in the future.
Combivir FDA-approval Timeline: History of FDA-approvals of all branded & generic formulations of lamivudine/zidovudine for Combivir formation.
Branded Drug:
1997-
- Combivir Tablet; Oral (150mg;300mg)
Active Ingredient(s): Lamivudine; Zidovudine
Applicant: ViiV Healthcare (U.K)
Generic Drugs:
2011-
- Lamivudine and Zidovudine Tablet; Oral (150mg;300mg)
Applicant: Chartwell Rx (U.S)
2012-
- Lamivudine and Zidovudine Tablet; Oral (150mg;300mg)
Applicant: Aurobindo Pharma Ltd (India)
- Lamivudine and Zidovudine Tablet; Oral (150mg;300mg)
Applicant: Lupin Ltd (India)
2014-
- Lamivudine and Zidovudine Tablet; Oral (150mg;300mg)
Applicant: Hetero Labs Ltd V (India)
2015-
- Lamivudine and Zidovudine Tablet; Oral (150mg;300mg)
Applicant: Strides Pharma (India)
- Lamivudine and Zidovudine Tablet; Oral (150mg;300mg)
Applicant: Hetero Labs Ltd III (India)
2017-
- Lamivudine and Zidovudine Tablet; Oral (150mg;300mg)
Applicant: PharmaCare (Australia)
- Lamivudine And Zidovudine Tablet; Oral (150mg;300mg)
Applicant: Aurobindo Pharma (India)
2018-
- Lamivudine And Zidovudine Tablet; Oral (150mg;300mg)
Applicant: Anda Repository (U.S)
- Lamivudine And Zidovudine Tablet; Oral (150mg;300mg)
Applicant: Macleods Pharms Ltd (India)
- Lamivudine And Zidovudine Tablet; Oral (150mg;300mg)
Applicant: Cipla (India)
2019-
- Lamivudine And Zidovudine Tablet; Oral (150mg;300mg)
Applicant: Mylan Labs Ltd (India)
Conclusion
The global combivir market is a rapidly growing field, with advancements in technology leading to improved outcomes for patients with HIV/AIDS. The global combivir market is expected to continue to grow in the coming years, as new technologies are developed. Overall, the global combivir market represents a significant opportunity for pharmaceutical industries, which are making strategic alliances to design an effective drug for AIDS treatment. With continued research and development, it is likely that even more treatments will become available in the future, leading to improved outcomes for patients through combivir.